HealthWarehouse.com Reports Results for Third Quarter 2026
Business Wire•13/11/2026•08:05 ET
0
Key Highlights
- ➤Q3 net sales $6.487 million, down 22.8% year over year
- ➤Q3 net loss $240,000 versus $72,000 loss last year
- ➤Q3 Adjusted EBITDA $123,000, down from $384,000
- ➤Nine-month net sales $18.967 million, down 51.5% year over year
- ➤Prescription sales fell 29.0% as compounded GLP-1 offerings ended
Expert Statements
Joseph Peters, President and CEO of HealthWarehouse.com
“Despite the continued challenges associated with the reduction in compounded GLP-1 sales, HealthWarehouse delivered positive Adjusted EBITDA for the period, reflecting our continued focus on operational efficiency, financial discipline, and building a sustainable business. These results are a testament to the extraordinary team at HealthWarehouse. Their dedication, hard work, and commitment to serving our customers and partners make achievements like this possible. We believe that same commitment to excellence has earned HealthWarehouse recognition as a 2026 Top Workplace by The Cincinnati Enquirer. I couldn't be prouder of this team and what we continue to accomplish together.”
Positive EBITDA Highlights Operational Strength and Team Execution
HealthWarehouse.com, Inc. (OTCQB:HEWA) announced today that its net sales for the third quarter ended September 30, 2026, totaled $6.51 million, a 23% decrease from the quarter ended September 30, 2025. In the first half of 2025, the U.S. Food and Drug Administration ended a nationwide program that allowed pharmacies, including HealthWarehouse.com, to offer compounded GLP-1 prescription medications during a shortfall in supply of proprietary brand-name versions.
Get started
Create a free account to read the full story.